Predictors of cardiovascular risk in familial hypercholesterolemia.

IF 3.8 3区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Current opinion in lipidology Pub Date : 2023-12-01 Epub Date: 2023-09-28 DOI:10.1097/MOL.0000000000000903
Manuel Jesús Romero-Jiménez, María Elena Mansilla-Rodríguez, Eva Nadiejda Gutiérrez-Cortizo
{"title":"Predictors of cardiovascular risk in familial hypercholesterolemia.","authors":"Manuel Jesús Romero-Jiménez,&nbsp;María Elena Mansilla-Rodríguez,&nbsp;Eva Nadiejda Gutiérrez-Cortizo","doi":"10.1097/MOL.0000000000000903","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>Familial hypercholesterolemia is associated with an increased risk of cardiovascular disease. The current international guidelines of the main scientific societies consider that, all people with Familial Hypercholesterolemia have a high or very high cardiovascular risk. However, the occurrence of atherosclerotic cardiovascular disease is very heterogeneous in this population. Stratifying risk within people with familial hypercholesterolemia is essential to identify individuals who require intensive cholesterol-lowering therapies.</p><p><strong>Recent findings: </strong>In the last year, several studies have been published focusing on the contribution of diabetes to Familial Hypercholesterolemia, the role of stroke, as a manifestation of atherosclerotic disease, and the external validation of the SAFEHEART risk equation in the English population diagnosed with Familial Hypercholesterolemia.</p><p><strong>Summary: </strong>It is necessary the development of a tool that allows us to identify, in a simple, reproducible, and universal way, patients who may have a high risk of suffering a cardiovascular event and who are susceptible to more intensive treatments to reduce cholesterol levels.</p>","PeriodicalId":11109,"journal":{"name":"Current opinion in lipidology","volume":" ","pages":"272-277"},"PeriodicalIF":3.8000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current opinion in lipidology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MOL.0000000000000903","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/28 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose of review: Familial hypercholesterolemia is associated with an increased risk of cardiovascular disease. The current international guidelines of the main scientific societies consider that, all people with Familial Hypercholesterolemia have a high or very high cardiovascular risk. However, the occurrence of atherosclerotic cardiovascular disease is very heterogeneous in this population. Stratifying risk within people with familial hypercholesterolemia is essential to identify individuals who require intensive cholesterol-lowering therapies.

Recent findings: In the last year, several studies have been published focusing on the contribution of diabetes to Familial Hypercholesterolemia, the role of stroke, as a manifestation of atherosclerotic disease, and the external validation of the SAFEHEART risk equation in the English population diagnosed with Familial Hypercholesterolemia.

Summary: It is necessary the development of a tool that allows us to identify, in a simple, reproducible, and universal way, patients who may have a high risk of suffering a cardiovascular event and who are susceptible to more intensive treatments to reduce cholesterol levels.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
家族性高胆固醇血症心血管风险的预测因素。
综述目的:家族性高胆固醇血症与心血管疾病风险增加有关。主要科学学会目前的国际指南认为,所有家族性高胆固醇血症患者都有很高或非常高的心血管风险。然而,动脉粥样硬化性心血管疾病的发生在这一人群中是非常异质的。对家族性高胆固醇血症患者的风险进行分层对于确定需要强化降胆固醇治疗的个体至关重要。最近的发现:在过去的一年里,发表了几项研究,重点关注糖尿病对家族性高胆固醇血症的影响,以及中风作为动脉粥样硬化疾病表现的作用,以及SAFEHEART风险方程在被诊断为家族性高胆固醇血症的英国人群中的外部验证。总结:有必要开发一种工具,使我们能够以简单、可重复和通用的方式识别,可能患有心血管事件的高风险患者,以及易接受更强化的治疗以降低胆固醇水平的患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Current opinion in lipidology
Current opinion in lipidology 医学-内分泌学与代谢
CiteScore
6.70
自引率
4.50%
发文量
64
审稿时长
6-12 weeks
期刊介绍: With its easy-to-digest reviews on important advances in world literature, Current Opinion in Lipidology offers expert evaluation on a wide range of topics from six key disciplines including nutrition and metabolism, genetics and molecular biology, and hyperlipidaemia and cardiovascular disease. Published bimonthly, each issue covers in detail the most pertinent advances in these fields from the previous year. This is supplemented by a section of Bimonthly Updates, which deliver an insight into new developments at the cutting edge of the disciplines covered in the journal.
期刊最新文献
Are the lipid-lowering effects of incretin-based therapies relevant for cardiovascular benefit? From clinical development to real-world outcomes with inclisiran. Oral agents for lowering lipoprotein(a). Universal screening for familial hypercholesterolaemia: how can we maximise benefits and minimise potential harm for children and their families? A contemporary snapshot of familial hypercholesterolemia registries.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1